Endometriosis — Deal Benchmarks & Valuation
Market Analysis
Endometriosis is one of the most actively transacted indications in women's health licensing. Phase 2 deals for endometriosis carry a median total deal value of $1.8B, with upfront payments ranging from $169M to $481M. The recommended deal structure allocates approximately 18% to upfront payments and 82% to milestones.
Milestone structures for endometriosis deals allocate $321M to development milestones, $336M to regulatory milestones, and $803M to commercial milestones. Royalty rates range from 7.9% to 15.8% at the base tier, with tiered escalation reaching 11.9%-19.8% on peak sales.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What are typical deal terms for endometriosis licensing?
What royalty rates are standard for endometriosis deals?
How are endometriosis deal milestones structured?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.